Buspirone

Generic Name
Buspirone
Brand Names
Buspar
Drug Type
Small Molecule
Chemical Formula
C21H31N5O2
CAS Number
36505-84-7
Unique Ingredient Identifier
TK65WKS8HL
Background

Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspiro...

Indication

Indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety.

Associated Conditions
Anxiety Disorders, Depression
Associated Therapies
-

Dexmed/Buspirone Synergism on Shivering

First Posted Date
2006-06-07
Last Posted Date
2016-06-29
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
8
Registration Number
NCT00334360
Locations
🇺🇸

Outcomes Research Institute, University of Louisville, Louisville, Kentucky, United States

Effects of Buspirone in Opiate Withdrawal

Phase 4
Completed
Conditions
First Posted Date
2006-05-16
Last Posted Date
2017-01-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Registration Number
NCT00326235
Locations
🇺🇸

VA New York Harbor Healthcare System - Brooklyn Campus, Brooklyn, New York, United States

Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar

First Posted Date
2005-09-15
Last Posted Date
2008-07-15
Lead Sponsor
Pfizer
Target Recruit Count
241
Registration Number
NCT00174226
Locations
🇺🇸

Pfizer Investigational Site, Woodstock, Vermont, United States

Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy

Phase 1
Completed
Conditions
First Posted Date
2005-09-14
Last Posted Date
2011-07-20
Lead Sponsor
Chugani, Diane C.
Target Recruit Count
20
Registration Number
NCT00166621
Locations
🇺🇸

PET Center/Children's Hospital of Michigan, Detroit, Michigan, United States

Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1

Phase 2
Completed
Conditions
First Posted Date
2005-09-08
Last Posted Date
2015-10-09
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
81
Registration Number
NCT00149617
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

Phase 4
Completed
Conditions
First Posted Date
2001-07-23
Last Posted Date
2009-09-25
Lead Sponsor
National Institute of Mental Health (NIMH)
Target Recruit Count
4000
Registration Number
NCT00021528
Locations
🇺🇸

Harbor UCLA Family Health Care Center, Harbor City, California, United States

🇺🇸

UCLA General Outpatient Psychiatry Clinic, Los Angeles, California, United States

🇺🇸

UCLA Internal Medicine Clinic, Los Angeles, California, United States

and more 38 locations
© Copyright 2024. All Rights Reserved by MedPath